Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
Portfolio Pulse from
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has opened three new clinical trial sites in Eastern Europe for its PAS-004 Phase 1 trial, targeting neurofibromatosis type 1 and other cancers. Initial dosing of Cohort 4 is complete, with interim data expected in Q1 2025.
January 14, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pasithea Therapeutics has expanded its PAS-004 Phase 1 trial to Eastern Europe, completing initial dosing of Cohort 4. This expansion could accelerate patient recruitment and data collection, with interim results expected in Q1 2025.
The opening of new clinical trial sites in Eastern Europe for Pasithea's PAS-004 Phase 1 trial is a significant development. It suggests progress in the trial, potentially leading to faster patient recruitment and data collection. The completion of initial dosing for Cohort 4 and the announcement of interim data expected in Q1 2025 could positively influence investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100